What is active surveillance in thyroid malignancy? What are the barriers to implementing it widely in Argentina?

Article Sidebar

Revista del HIBA 2020, vol. 41, nro. 2
PDF (Spanish)

Main Article Content

Fabián Pitoia
Área de Investigación, División Endocrinología. Hospital de Clínicas, Universidad de Buenos Aires. Buenos Aires, Argentina

Abstract

.

Downloads

##plugins.themes.bootstrap3.displayStats.noStats##
Published: 2021-06-30
DOI: https://doi.org/10.51987/revhospitalbaires.v41i2.91
Keywords:
humanos, neoplasias de la tiroides/terapia, espera vigilante/estadística & datos numéricos, argentina, calidad de vida, neoplasia de la tiroides/psicología, progresión de la enfermedad

Article Details

Issue

Vol. 41 No. 2 (2021): Revista del Hospital Italiano de Buenos Aires

Section

Ask the expert
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Author Biography

Fabián Pitoia, Área de Investigación, División Endocrinología. Hospital de Clínicas, Universidad de Buenos Aires. Buenos Aires, Argentina

Presidente Electo de la Sociedad Latinoamericana de Tiroides Jefe de la Sección Tiroides. Coordinador del Área de Investigación, División Endocrinología. Hospital de Clínicas, Universidad de Buenos Aires, Argentina

How to Cite

1.
Pitoia F. What is active surveillance in thyroid malignancy? What are the barriers to implementing it widely in Argentina? Rev Hosp Ital B.Aires [Internet]. 2021 Jun. 30 [cited 2026 Jul. 31];41(2):p. 79-81. Available from: https://ojs.hospitalitaliano.org.ar/index.php/revistahi/article/view/91

References

Sugitani I, Toda K, Yamada K, et al. Three distinctly different kinds of papillary thyroid microcarcinoma should be recognized: our treatment strategies and outcomes. World J Surg 2010;34:1222- 1231.

Ito Y, Miyauchi A, Kihara M, et al. Patient age is significantly related to the progression of papillary microcarcinoma of the thyroid under observation. Thyroid 2014; 24:27-34.

Oda H, Miyauchi A, Ito Y, et al. Incidences of Unfavorable Events in the Management of Low-Risk Papillary Microcarcinoma of the Thyroid by Active Surveillance Versus Immediate Surgery. Thyroid 2016;26:150-155.

Kwon H, Oh HS, Kim M, et al. Active Surveillance for Patients With Papillary Thyroid Microcarcinoma: A Single Center's Experience in Korea. J Clin Endocrinol Metab 2017;102:1917-1925.

Tuttle RM, Fagin JA, Minkowitz G, et al. Natural History and Tumor Volume Kinetics of Papillary Thyroid Cancers During Active Surveillance. JAMA Otolaryngol Head Neck Surg 2017; 143:1015-1020.

Ramundo V, Sponziello M, Falcone R, et al. Low-risk papillary thyroid microcarcinoma: Optimal management toward a more conservative approach. J Surg Oncol 2020; 121:958-963.

Sakai T, Sugitani I, Ebina A, et al. Active Surveillance for T1bN0M0 Papillary Thyroid Carcinoma. Thyroid 2019; 29:59- 63

Smulever A, Pitoia F. Active surveillance in papillary thyroid carcinoma: not easily accepted but possible in Latin America. Arch Endocrinol Metab 2019; 63:462-469.

Molinaro E, Campopiano MC, Pieruzzi L, et al. Active Surveillance in Papillary Thyroid Microcarcinomas is Feasible and Safe: Experience at a Single Italian Center. J Clin Endocrinol Metab 2020;105(3): e172-e180.

Smulever A, Pitoia F. High rate incidence of post-surgical adverse events in patients with low-risk papillary thyroid cancer who did not accept active surveillance. Endocrine. 2020; 69(3):587-59.

Pitoia F, Smulever A. “Vigilancia activa encubierta” y los costos de la ausencia de implementación de la “cirugía diferida” en Argentina. Rev Arg